0.96 USD
▼-0.37-27.45%
盘后 0.80 0.00%
2026-09-16
市值
$987.90K
市盈率
—
EPS
-78.31
股息率
—
52 周区间
0.61 – 59.40
成交量
3.30M
Beta
1.19
目标价
—
52W 低 0.6152W 高 59.40
价格走势
公司简介
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse m...